Ask AI
ASH 2025 MDS and MPNs

CE / CME

New Data and Clinical Implications in MPNs and MDS: ASH 2025 Highlights

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Released: February 26, 2026

Expiration: August 25, 2026

Activity

Progress
1 2 3
Course Completed

Introduction

In this module, Rami Komrokji, MD, and Amer Zeidan, MBBS, MHS​, explore key clinical trial updates in myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs), including 96-week data on ruxolitinib plus pelabresib in myelofibrosis (MF), emerging immune-based strategies targeting mutant CALR in essential thrombocythemia (ET) and MF, and new analyses in higher- and lower-risk MDS.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slidesets, which can be found here or downloaded by clicking on any of the slide thumbnails in the module alongside the expert commentary.

Please note that Decera Clinical Education plans to measure the educational impact of this activity. Some questions are asked twice: once at the beginning of the activity, and once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your individual responses will not be shared. Thank you in advance for helping us assess the impact of this education.

Before continuing with this educational activity, please take a moment to answer the following questions.

How many people with MDS or MPNs do you provide care for in a typical month?

For those who practice in academic or community settings, please indicate your practice setting:

In the phase III MANIFEST-2 trial evaluating pelabresib plus ruxolitinib vs ruxolitinib plus placebo as first-line therapy in JAK inhibitor–naive MF, the 96-week update presented at the ASH Annual Meeting 2025 reported which of the following findings regarding safety and efficacy among evaluable patients who remained on treatment at Week 96?

When discussing the clinical implications of the IMerge post hoc analysis with a patient who has lower‑risk MDS and red blood cell (RBC) transfusion–dependent anemia, which of the following would you tell her best reflects how treatment-emergent cytopenias during early imetelstat therapy relate to clinical benefit?

Based on updated phase I data from the INCA033989-101/102 studies, which statement best reflects the clinical and biologic activity of INCA033989 as monotherapy or in combination with ruxolitinib in patients with CALR -mutated MF who were resistant to or ineligible for JAK inhibitor therapy?